Clinical Testing News and Research

RSS

Scientist develop mathematical model that predicts how individuals respond to cancer treatment

Vittorio Cristini, PhD, uses the example of an airplane to explain what he does in cancer research. "Before calculus," he says, "people couldn't really design a plane that would fly. You can do it by trial and error, but it would probably take centuries." Dr. Cristini has a faster way to try to understand cancer treatment. Like airplane designers today, he uses a mathematical model.

13 Aug 2013

Patients with rare epilepsy aphasia share mutations on same gene

Some patients with a rare type of epilepsy called epilepsy aphasia have something else in common. They have mutations in the same gene. Epilepsy aphasia disorders are characterized by seizures and speech abnormalities.

13 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

Essentially, what an artificial pancreas would be doing is taking the blood glucose results from a continuous monitor and taking the data that the patient puts in about the amount she/he is eating, and then adjusting the amount of insulin being delivered by the pump based on a mathematical formula that would be very personalized to that patient.

25 Jul 2013

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting.

23 Jul 2013

Heart transplant could get a second chance to save life

Human hearts which are not used each year because they are deemed unsuitable for an organ transplant could get a second chance to save a life, with the help of new research taking place in the North East.

11 Jul 2013

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

A chemical component present in the nightshade family of plants is one of the world's most tenaciously addictive substances. It is the nicotine contained in tobacco and found in high concentrations in cigarettes. Smoking remains a global scourge; in the U.S. it is the leading source of preventable death.

3 Jul 2013

AtheroNova starts AHRO-001 Phase 1 clinical trial for treatment of atherosclerosis

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers.

25 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Emory University today announced an innovative new public-private drug development enterprise that will transition scientific discoveries more rapidly and efficiently from university laboratories into the marketplace. The new venture is expected to provide global solutions to address worldwide drug development and commercialization needs.

15 Jun 2013

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in preclinical models in contrast to existing GABAA receptor non-selective agonists, such as benzodiazepines.

10 Jun 2013

Scientists work together to optimize the quality, availability of fecal microbiota transplants

Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.

4 Jun 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

Inhibiting powerful protein with new agents may supply broad benefit for lymphoma patients

A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.

14 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.

6 May 2013

Researchers issue statement regarding use of unproven stem cell therapies

An international group of leading stem cell researchers has issued a statement that specifies concerns about the development and use of unproven stem cell therapies.

4 May 2013

EventusDx receives CE mark designation for Octava Pink breast cancer test

Eventus Diagnostics, Inc. today announced that it has received CE mark designation for its Octava Pink™ breast cancer test intended for confirmatory use in women who have received negative mammography results.

2 May 2013

Glide Pharma awarded contract from Pfenex Inc. to develop a solid formulation of recombinant anthrax vaccine

Glide Pharma® today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfēnex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.

30 Apr 2013